
WHAT IS CLAIMED IS:

1. Use of a composition comprising a bromodomain inhibitor in the manufacture of a medicament for promoting T-cell activation during cancer immunotherapy, wherein the bromodomain inhibitor in the medicament reduces PD-L1 expression in antigen presenting cells ("APCs").

2. The use of claim 1, wherein bromodomain inhibitor-treated APCs restore responsiveness of anergic CD4+ T cells.

3. The use of claims 1 or 2 , wherein the bromodomain inhibitor is a Bromodomain and extraterminal ("BET") inhibitor.

4. The use of claim 3, wherein the BET inhibitor comprises the following chemical formula: 

.


5. The use of claim 1, in further combination with an immunostimulatory agent.

6. The use of claim 5, wherein the immunostimulatory agent comprises an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or a combination thereof.

7. The use of claim 6, wherein the immunostimulatory agent is MPDL3280A.

8. The use of any one of claims 5 to 7, wherein the bromodomain inhibitor is a Bromodomain and extraterminal ("BET") inhibitor.

9. The use of claim 8, wherein the BET inhibitor comprises the following chemical formula:



.

10. The use of any one of claims 5 to 9, wherein the medicament further comprises an immunogenic agent.

11. A method for *ex vivo* activation of antigen-specific T cells, comprising: treating a population of antigen presenting cells ("APCs") with a bromodomain inhibitor; and adding a population of T cells to the population of treated APCs.

12. The method of claim 11, wherein the APCs comprise dendritic cells or macrophages.